Delos Capital
VC Fund
New York, United States
Delos Capital is a lower-middle market private equity investment firm based in New York City. The Fund was formed in 2013 to invest in complex processes through Control Buyouts, Strategic Partnerships and Distressed Buyouts in companies with EBITDA of $10 – $30 million.
- Total investments:
- 31
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $275M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Delos Capital invests in
Stages Delos Capital invests in
Countries Delos Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Tim Xiao
|
|||
|
Matt Constantino
|
|||
|
Sanjay Sanghoee
|
|||
Investment Focus
Industry
- Biotechnology 15 (48%)
- Health Care 13 (42%)
- Medical 7 (23%)
- Therapeutics 7 (23%)
- Pharmaceutical 7 (23%)
Stage
- Series B 10 (32%)
- Series A 5 (16%)
- Series C 5 (16%)
- Private Equity 4 (13%)
- Series D 2 (6%)
Country
- United States 22 (71%)
- China 2 (6%)
- Germany 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Tim Xiao
Partner
|
Partner | Total investments: 3 | Find email | |
|
Matt Constantino
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
|
Sanjay Sanghoee
CFO/COO
|
CFO/COO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
STRM.BIO
|
STRM.BIO specializes in the fields of biotechnology and life science. | $8M / Seed / Jan 07, 2026 | |
Ensoma
|
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. | $53M / Sep 22, 2025 | |
Cardurion Pharmaceuticals
|
Cardurion Pharmaceuticals is a Boston-based biotechnology company focused on developing novel therapeutics for the treatment of heart failure and other cardiovascular diseases. The company is advancing groundbreaking clinical programs targeting PDE9 and CaMKII inhibition, leveraging its expertise in cardiovascular signaling pathways to addressunmet patient needs. | $260M / Series B / Jul 16, 2024 | |
AltruBio
|
AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases.AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment ofcancer and immune-related inflammatory diseases.With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discovery and development of novel therapeutics for unmet medical needs.Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics.Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages. | $225M / Series B / May 21, 2024 | |
Zenas BioPharma
|
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA. | $200M / Series C / May 07, 2024 | |
Avenzo Therapeutics
|
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $150M / Series A / Mar 26, 2024 | |
Instylla
|
Instylla’s focus is to leverage hydrogel technology . | $30M / Series C / Aug 15, 2023 | |
Eccogene
|
Eccogene is a Health Care Company. | $25.2M / Series B / Jun 12, 2023 | |
|
Ensoma
|
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. | $50M / Series B / May 16, 2023 | |
Rejoni
|
Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $26.3M / Series B / Dec 07, 2022 | |
| See all 31 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Delos Capital invest in?
Delos Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 31 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Delos Capital?
Public channels for Delos Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Delos Capital?
The team at Delos Capital includes Tim Xiao (Partner), Matt Constantino (Founding Partner) and Sanjay Sanghoee (CFO/COO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
